Life Sciences Archives - Page 5 of 21 - Becker's Hospital Review

GLP-1 fails to slow Alzheimer's | Measles vaccine immunity fades after 10 years | Spinal gene therapy approved | FDA drug voucher program stirs concern | 5 new drug shortages

Vaccine durability questions, gene therapy gains and FDA policy concerns. November 26, 2025 1. Novo Nordisk GLP-1 fails to slow Alzheimer's in trials Full story 2. Measles vaccine immunity fades after 10 years: Study Full story 3. 2026 strategy check:…

FDA to trim gene therapy approval | Pfizer to sell $508M BioNTech stake | 1st biosimilar to breast cancer drug approved | Ozempic, Wegovy to be sold at a discount | FDA approves HIV self-test

From gene therapy cuts to HIV tests, the key FDA moves this week. November 19, 2025 1. After patient deaths, FDA to trim gene therapy's approval Full story 2. Pfizer to sell $508M stake in BioNTech Full story 3. Prevention…

Pfizer to buy Metsera for $10B | Texas sues Tylenol makers again | GI drug recalled | FDA names new drug center chief | Patient dies in Intellia trial

Drug recalls, FDA updates and a $10B Pfizer deal lead this week. November 12, 2025 1. Pfizer prevails in $10B bidding war for Metsera Full story 2. Texas files 2nd lawsuit against Tylenol makers Full story 3. 2026 AI priorities:…

Metsera, Novo Nordisk sued over failed merger | Kenvue bought for $48.7B | Cancer risk forces blood pressure drug recall | 14 drugs in shortage

Mergers, recalls and drug shortages shaping pharma this week. November 5, 2025 1. Pfizer sues Metsera, Novo Nordisk over failed merger Full story 2. Kimberly-Clark to buy Tylenol maker Kenvue for $48.7B Full story 3. In a burnout era, 95%+…

Tylenol makers sued | Previously pulled cancer drug reapproved | 2 gene therapy trials halted | Stricter oversight of foreign drugmakers proposed

Regulatory action, trial pauses and renewed cancer drug approvals October 29, 2025 1. Texas sues Tylenol makers, alleging drug's links to autism Full story 2. FDA approves cancer drug previously pulled from market Full story 3. Stop chasing short-term fixes.…

Tylenol maker defends product safety | 9 drugs fast-tracked | Pa. pharmacy fined for distributing unauthorized drugs | H-1B visa fees clarified

Pharma regulation, approvals and policy developments to watch October 22, 2025 1. Tylenol maker defends product amid FDA scrutiny Full story 2. FDA taps 1st 9 drugs for fast-track program Full story 3. Missed codes = missed revenue. How top…

FDA green-lights skin cancer drug | 5 GLP-1 updates | Cancer AI research platform debuts | CDC projects modest flu season

FDA approvals, GLP-1 updates and new cancer research tools. October 15, 2025 1. FDA approves drug for high-risk skin cancer Full story 2. 5 GLP-1 updates Full story 3. Why ASC leaders are rethinking robotics: Lessons from UCSD and Memorial…

Treatment for rare disease OK'd | Costco to sell Wegovy, Ozempic | Mifepristone approved before shutdown | Surgeons general warn of HHS instability

October 8, 2025 1. FDA approves first new treatment for rare disease in 10 years Full story 2. Costco to sell Wegovy, Ozempic Full story 3. Patient-reported outcomes are powering real-time decisions at Norton and Endeavor. Details here. 4. 'Bigger…

Breast cancer drug approved | Government shutdown: What to know | HHS to speed up gene therapy progress | Breakdown of GLP-1 approvals

October 1, 2025 1. FDA approves breast cancer drug Full story 2. Government shutdown begins: What healthcare leaders should know Full story 3. Labor spend doesn't have to undermine ROI goals. Find a smarter staffing model here. 4. GLP-1 drug…

1st Barth syndrome treatment OK'd | Lilly: New GLP-1 more effective than competitor | 6 drugs in shortage | US weighs visa exemptions for physicians

September 24, 2025 1. Eli Lilly claims its GLP-1 outperforms semaglutide in trial Full story 2. FDA approves 1st Barth syndrome treatment Full story 3. New protocols + EHRs are falling short on inpatient diabetes care. Why and what to…